skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management

Review

(3062) Views  (1352) Full article downloads

Authors: Sarah Rofaiel, Esther N Muo, Shaker A Mousa

Published Date September 2010 Volume 2010:3 Pages 129 - 143
DOI: http://dx.doi.org/10.2147/PGPM.S10789

Sarah Rofaiel1, Esther N Muo1, Shaker A Mousa1,2
1The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, New York, USA; 2King Saud University, Riyadh, Saudi Arabia

Abstract: There is wide individual variability in the pharmacokinetics, pharmacodynamics, and tolerance to anticancer drugs within the same ethnic group and even greater variability among different ethnicities. Pharmacogenomics (PG) has the potential to provide personalized therapy based on individual genetic variability in an effort to maximize efficacy and reduce adverse effects. The benefits of PG include improved therapeutic index, improved dose regimen, and selection of optimal types of drug for an individual or set of individuals. Advanced or metastatic breast cancer is typically treated with single or multiple combinations of chemotherapy regimens including anthracyclines, taxanes, antimetabolites, alkylating agents, platinum drugs, vinca alkaloids, and others. In this review, the PG of breast cancer therapeutics, including tamoxifen, which is the most widely used therapeutic for the treatment of hormone-dependent breast cancer, is reviewed. The pharmacological activity of tamoxifen depends on its conversion by cytochrome P450 2D6 (CYP2D6) to its abundant active metabolite, endoxifen. Patients with reduced CYP2D6 activity, as a result of either their genotype or induction by the coadministration of other drugs that inhibit CYP2D6 function, produce little endoxifen and hence derive limited therapeutic benefit from tamoxifen; the same can be said about the different classes of therapeutics in breast cancer. PG studies of breast cancer therapeutics should provide patients with breast cancer with optimal and personalized therapy.

Keywords: pharmacogenomics, genetic, pharmacokinetic, pharmacodynamic, personalized medicine, pharmacotherapy, anticancer drugs, efficacy, safety




 

Other articles by Professor Shaker Mousa



Readers of this article also read:

Genomics and proteomics: Applications in autoimmune diseases
Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine
The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent
Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine
Antiplatelet agents and proton pump inhibitors – personalizing treatment
Quality of life of breast cancer patients medicated with anti-estrogens, 2 years after acupuncture treatment: a qualitative study
FACE: the barefaced facts of AI potency
Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy
Clinical application of high throughput molecular screening techniques for pharmacogenomics
Role of cytochrome P450 genotype in the steps toward personalized drug therapy